Population-level impact of ibrutinib for chronic lymphocytic leukemia in British Columbia, Canada

References

• Owen C, Banerji V, Johnson N, et al. Canadian evidence-based guideline for frontline treatment of chronic lymphocytic leukemia: 2022 update. Leuk Res. 2023;125:107016.
   PubMed Web of Science ®Google Scholar
• Hallek M. Chronic lymphocytic leukemia: 2020 update on diagnosis, risk stratification and treatment. Am J Hematol.. 2019;94(11):1266–1287.
   PubMed Web of Science ®Google Scholar
• Hallek M, Fischer K, Fingerle-Rowson G, et al. Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial. Lancet. 2010;376(9747):1164–1174.
   PubMed Web of Science ®Google Scholar
• Fischer K, Cramer P, Busch R, et al. Bendamustine in combination with rituximab for previously untreated patients with chronic lymphocytic leukemia: a multicenter phase II trial of the german chronic lymphocytic leukemia study group. J Clin Oncol. 2012;30(26):3209–3216.
   PubMed Web of Science ®Google Scholar
• Goede V, Fischer K, Busch R, et al. Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions. N Engl J Med. 2014;370(12):1101–1110.
   PubMed Web of Science ®Google Scholar
• Robak T, Dmoszynska A, Solal-Céligny P, et al. Rituximab plus fludarabine and cyclophosphamide prolongs progression-free survival compared with fludarabine and cyclophosphamide alone in previously treated chronic lymphocytic leukemia. J Clin Oncol. 2010;28(10):1756–1765.
   PubMed Web of Science ®Google Scholar
• Byrd JC, Furman RR, Coutre SE, et al. Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia. N Engl J Med. 2013;369(1):32–42.
   PubMed Web of Science ®Google Scholar
• Woyach JA, Johnson AJ, Byrd JC. The B-cell receptor signaling pathway as a therapeutic target in CLL. Blood. 2012;120(6):1175–1184.
   PubMed Web of Science ®Google Scholar
• Byrd JC, Brown JR, O'Brien S, et al. Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia. N Engl J Med. 2014;371(3):213–223.
   PubMed Web of Science ®Google Scholar
• O'Brien S, Furman RR, Coutre SE, et al. Ibrutinib as initial therapy for elderly patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: an open-label, multicentre, phase 1b/2 trial. Lancet Oncol. 2014;15(1):48–58.
   PubMed Web of Science ®Google Scholar
• Farooqui MZH, Valdez J, Martyr S, et al. Ibrutinib for previously untreated and relapsed or refractory chronic lymphocytic leukaemia with TP53 aberrations: a phase 2, single-arm trial. Lancet Oncol. 2015;16(2):169–176.
   PubMed Web of Science ®Google Scholar
• Shanafelt TD, Wang XV, Kay NE, et al. Ibrutinib–rituximab or chemoimmunotherapy for chronic lymphocytic leukemia. N Engl J Med. 2019;381(5):432–443.
   PubMed Web of Science ®Google Scholar
• Woyach JA, Ruppert AS, Heerema NA, et al. Ibrutinib regimens versus chemoimmunotherapy in older patients with untreated CLL. N Engl J Med. 2018;379(26):2517–2528.
   PubMed Web of Science ®Google Scholar
• Ahn IE, Tian X, Wiestner A. Ibrutinib for chronic lymphocytic leukemia with TP53 alterations. N Engl J Med. 2020;383(5):498–500.
   PubMed Web of Science ®Google Scholar
• Aarup K, Rotbain EC, Enggaard L, et al. Real-world outcomes for 205 patients with chronic lymphocytic leukemia treated with ibrutinib. Eur J Haematol. 2020;105(5):646–654.
   PubMed Web of Science ®Google Scholar
• Frei CR, Le H, McHugh D, et al. Outcomes in chronic lymphocytic leukemia patients on novel agents in the US veterans health administration system. Leuk Lymphoma. 2021;62(7):1664–1673.
   PubMed Web of Science ®Google Scholar
• Pula B, Iskierka-Jazdzewska E, Dlugosz-Danecka M, et al. Long-term efficacy of ibrutinib in relapsed or refractory chronic lymphocytic leukemia: results of the polish adult leukemia study group observational study. Anticancer Res. 2020;40(7):4059–4066.
   PubMed Web of Science ®Google Scholar
• Mato AR, Nabhan C, Thompson MC, et al. Toxicities and outcomes of 616 ibrutinib-treated patients in the United States: a real-world analysis. Haematologica. 2018;103(5):874–879.
   PubMed Web of Science ®Google Scholar
• Woyach JA, Ruppert AS, Guinn D, et al. BTKC481S-Mediated resistance to ibrutinib in chronic lymphocytic leukemia. J Clin Oncol. 2017;35(13):1437–1443.
   PubMed Web of Science ®Google Scholar
• Burger JA, Barr PM, Robak T, et al. Long-term efficacy and safety of first-line ibrutinib treatment for patients with CLL/SLL: 5 years of follow-up from the phase 3 RESONATE-2 study. Leukemia. 2020;34(3):787–798.
   PubMed Web of Science ®Google Scholar
• Byrd JC, Hillmen P, O'Brien S, et al. Long-term follow-up of the RESONATE phase 3 trial of ibrutinib vs ofatumumab. Blood. 2019;133(19):2031–2042.
   PubMed Web of Science ®Google Scholar
• Michallet AS, Campidelli A, Lequeu H, et al. Ibrutinib in very elderly patients with relapsed/refractory chronic lymphocytic leukemia: a real-world experience of 71 patients treated in France: a study from the french innovative leukemia organization (FILO) group. p. Am J Hematol. 2017;92(6):E105–E107.
   PubMed Web of Science ®Google Scholar
• Göçer M, Kurtoğlu E. Safety and efficacy analysis of ibrutinib in 32 patients with CLL and various B-cell lymphomas: real-world data from a single-center study in Turkey. Blood Res. 2020;55(4):206–212.
   PubMed Web of Science ®Google Scholar
• Nuttall E, Tung J, Trounce E, et al. Real-world experience of ibrutinib therapy in relapsed chronic lymphocytic leukemia: results of a single-center retrospective analysis. J Blood Med. 2019;10:199–208.
   PubMed Web of Science ®Google Scholar
• Government of British Columbia. BC Population Estimates. 2022. https://www2.gov.bc.ca/gov/content/data/statistics/people-population-community/population/population-estimates
   Google Scholar
• Winqvist M, Andersson PO, Asklid A, et al. Long-term real-world results of ibrutinib therapy in patients with relapsed or refractory chronic lymphocytic leukemia: 30-month follow up of the swedish compassionate use cohort. Haematologica. 2019;104(5):e208–10–e210.
   Web of Science ®Google Scholar
• Archibald WJ, Rabe KG, Kabat BF, et al. Atrial fibrillation in patients with chronic lymphocytic leukemia (CLL) treated with ibrutinib: risk prediction, management, and clinical outcomes. Ann Hematol. 2021;100(1):143–155.
   PubMed Web of Science ®Google Scholar
• Brown JR, Byrd JC, Ghia P, et al. Cardiovascular adverse events in patients with chronic lymphocytic leukemia receiving acalabrutinib monotherapy: pooled analysis of 762 patients. Haematologica. 2022;107(6):1335–1346.
   PubMed Web of Science ®Google Scholar
• Dickerson T, Wiczer T, Waller A, et al. Hypertension and incident cardiovascular events following ibrutinib initiation. Blood. 2019;134(22):1919–1928.
   PubMed Web of Science ®Google Scholar
• Fradley MG, Gliksman M, Emole J, et al. Rates and risk of atrial arrhythmias in patients treated with ibrutinib compared with cytotoxic chemotherapy. Am J Cardiol. 2019;124(4):539–544.
   PubMed Web of Science ®Google Scholar
• Salem JE, Manouchehri A, Bretagne M, et al. Cardiovascular toxicities associated with ibrutinib. J Am Coll Cardiol. 2019;74(13):1667–1678.
   PubMed Web of Science ®Google Scholar
• Akhtar OS, Attwood K, Lund I, et al. Dose reductions in ibrutinib therapy are not associated with inferior outcomes in patients with chronic lymphocytic leukemia (CLL). Leuk Lymphoma. 2019;60(7):1650–1655.
   PubMed Web of Science ®Google Scholar
• Hou JZ, Ryan K, Du S, et al. Real-world ibrutinib dose reductions, holds and discontinuations in chronic lymphocytic leukemia. Futur Oncol. 2021;17(35):4969–4972.
   Web of Science ®Google Scholar
• Bose P, Chen LS, Gandhi V. Ibrutinib dose and clinical outcome in chronic lymphocytic leukemia - learning from the ‘real world. Leuk Lymphoma. 2019;60(7):1603–1605.
   PubMed Web of Science ®Google Scholar
• Alexander W, Davis S, Ramakrishna R, et al. Outcomes of reduced frequency dosing of ibrutinib in chronic lymphocytic leukemia patients following complete or partial remission: a pilot study. J Hematol. 2020;9(3):55–61.
   PubMedGoogle Scholar
• Chen LS, Bose P, Cruz ND, et al. A pilot study of lower doses of ibrutinib in patients with chronic lymphocytic leukemia. Blood. 2018;132(21):2249–2259.
   PubMed Web of Science ®Google Scholar
• Ysebaert L, Aurran-Schleinitz T, Dartigeas C, et al. Real-world results of ibrutinib in relapsed/refractory CLL in France: early results on a large series of 428 patients. Am J Hematol. 2017;92(8):E166–E168.
   PubMed Web of Science ®Google Scholar
• O'Brien SM, Byrd JC, Hillmen P, et al. Outcomes with ibrutinib by line of therapy and post-ibrutinib discontinuation in patients with chronic lymphocytic leukemia: phase 3 analysis. Am J Hematol. 2019;94(5):554–562.
   PubMed Web of Science ®Google Scholar
• Byrd JC, Hillmen P, Ghia P, et al. Acalabrutinib versus ibrutinib in previously treated chronic lymphocytic leukemia: results of the first randomized phase III trial. J Clin Oncol. 2021;39(31):3441–3452.
   PubMed Web of Science ®Google Scholar
• Brown JR, Hillmen P, Eichhorst B, et al. CLL-115 first interim analysis of ALPINE study: results of a phase 3 randomized study of zanubrutinib vs ibrutinib in patients with relapsed/refractory (R/R) chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL). Clin Lymphoma Myeloma Leuk. 2022;22(Suppl 2):S266.
   Google Scholar
• Mato A, Nabhan C, Lamanna N, et al. The connect CLL registry: final analysis of 1494 patients with chronic lymphocytic leukemia across 199 US sites. Blood Adv. 2020;4(7):1407–1418.
   PubMed Web of Science ®Google Scholar
• Hampel PJ, Ding W, Call TG, et al. Rapid disease progression following discontinuation of ibrutinib in patients with chronic lymphocytic leukemia treated in routine clinical practice. Leuk Lymphoma. 2019;60(11):2712–2719.
   PubMed Web of Science ®Google Scholar